Cambridge Cognition, a company that develops digital solutions for assessing brain health, has partnered with ActiGraph, a provider of wearable technologies for clinical trials. This collaboration aims to provide a comprehensive view of mental and physical capabilities through a suite of assessments.
ActiGraph’s Accelerant partnership program is focused on advancing the use of digital health technologies (DHTs) in clinical development by streamlining access to raw data streams for CROs and technology vendors. Through this strategic partnership, Cambridge Cognition and ActiGraph will leverage their expertise in digital data collection to enhance assessment capabilities in CNS trials, particularly in areas with high unmet needs such as schizophrenia and dementia.
Cambridge Cognition offers touchscreen and voice-based digital assessments for cognition and other brain health indicators, with over 30 years of experience in this field. Their e-clinical technology solutions can be used in-home or in a clinical setting.
Francesca Cormack, chief scientist at Cambridge Cognition, stated: “CNS disorders present a range of symptoms that impact daily life, but are often not adequately addressed by current treatments. Our partnership with ActiGraph combines expertise in objective digital measures of actigraphy, speech, and cognition, accelerating the development of treatments and improving efficiency in clinical trials.”
Christine Guo, chief scientific officer at ActiGraph, added: “Digital health technologies enable us to collect objective data in a patient’s everyday life, which is crucial in CNS disorders where traditional assessments are prone to subjective biases. We are thrilled about our partnership with Cambridge Cognition to provide advanced insights in CNS trials.”
